AbelZeta Receives EMA PRIME Designation for C-CAR168 in Lupus Nephritis and Systemic Lupus Erythematosus

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted PRIority MEdicines (PRIME) designation for C-CAR168, the Company’s novel autologous anti-CD20/BCMA CAR-T product candidate, for the treatment of refractory Systemic Lupus Erythematosus (SLE), with or without Lupus Nephritis (LN). The post AbelZeta Receives EMA PRIME Designation for C-CAR168 in Lupus Nephritis and Systemic Lupus Erythematosus appeared first on AbelZeta Pharma .